These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 8768000)

  • 1. [Prevention and treatment of coronary heart disease: lowering LDL, increasing HDL or monitoring both?].
    Windler E
    Internist (Berl); 1996 Jun; 37(6):643-6. PubMed ID: 8768000
    [No Abstract]   [Full Text] [Related]  

  • 2. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Coronary heart disease patient after myocardial infarct. Must LDL cholesterol now be reduced to 70 mg/dl?]].
    MMW Fortschr Med; 2005 Dec; 147(49-50):17-8. PubMed ID: 16401004
    [No Abstract]   [Full Text] [Related]  

  • 4. [The role of cholesterol-lowering drugs in prevention of coronary heart disease].
    Skałuba Z; Undas R
    Przegl Lek; 1998; 55(7-8):382-7. PubMed ID: 10021881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid management with statins. The lower the better?
    Laufs U; Liao JK; Böhm M
    Z Kardiol; 2004 Jan; 93(1):4-9. PubMed ID: 14740235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
    Lim PO; Yee KM
    Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
    [No Abstract]   [Full Text] [Related]  

  • 7. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
    März W
    MMW Fortschr Med; 2004 Jul; 146(27-28):53. PubMed ID: 15526673
    [No Abstract]   [Full Text] [Related]  

  • 9. [Optimal lipid lowering therapy for coronary heart diseases patients in secondary prevention: moderate or aggressive LDL decrease preferred?].
    MMW Fortschr Med; 2006 Nov; 148(48):54-5. PubMed ID: 17615773
    [No Abstract]   [Full Text] [Related]  

  • 10. [Lipid therapy. Goal and use in prevention of coronary heart disease].
    Windler E; Greten H
    Internist (Berl); 1996 Dec; 37(12):1244-8. PubMed ID: 9081925
    [No Abstract]   [Full Text] [Related]  

  • 11. Lowering cholesterol levels in patients with coronary heart disease. The LIPID Study Management Committee.
    Med J Aust; 1995 May; 162(9):455-6. PubMed ID: 7746199
    [No Abstract]   [Full Text] [Related]  

  • 12. The statin era: in search of the ideal lipid regulating agent.
    Shepherd J
    Heart; 2001 Mar; 85(3):259-64. PubMed ID: 11179260
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LDL-Cholesterol is the King.
    Goumas GS
    Angiology; 2009; 60(3):387-8. PubMed ID: 19497926
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?
    Gotto AM; Kuller LH
    Circulation; 2002 Jan; 105(2):136-9. PubMed ID: 11790688
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cholesterol: how and when to treat it?].
    Masana Marín L
    Med Clin (Barc); 1985 Oct; 85(10):423-5. PubMed ID: 4079497
    [No Abstract]   [Full Text] [Related]  

  • 19. Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or horses for courses?
    Watts GF
    Eur Heart J; 2004 May; 25(9):716-9. PubMed ID: 15120879
    [No Abstract]   [Full Text] [Related]  

  • 20. [For my coronary heart disease patients I strive for a 70 mg/dl LDL level (interview by Dr. med. Dirk Einecke)].
    Bode C
    MMW Fortschr Med; 2005 Jun; 147(23):49. PubMed ID: 15981909
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.